Catalent to Acquire Acorda Therapeutics’ Manufacturing and Packaging Operations
Acorda’s Chelsea, MA facility will serve as a global center of excellence in the Catalent network for spray-dried dispersion and dry powder encapsulation and packaging.
Catalent announced on Jan. 13, 2021 that it will acquire the manufacturing and packaging operations of Acorda Therapeutics, a US-based biotechnology company.
Through the agreement, Catalent will have access to Acorda’s 90,000-ft2 Chelsea, MA facility, which will serve as a global center of excellence in the Catalent network for spray-dried dispersion and dry powder encapsulation and packaging, Catalent said in a company press release. Additionally, Catalent will handle the commercial manufacture of Acorda’s INBRIJA, a prescription medicine used to treat hypomobility or off episodes in adults with Parkinson’s disease treated with regular carbidopa/levodopa medicine.
"Catalent is a premier partner to companies working on multiple forms of inhaled drug delivery, from early-stage development to commercial-scale supply," said Jonathan Arnold, president of Oral and Specialty Delivery at Catalent, in the press release. “This acquisition complements our existing US-based capabilities in metered-dose and nasal inhalation by adding an experienced team of people and a premier facility enabling us to provide customers with extended capabilities for commercial-scale filling and packaging of dry powder inhalers.”
Source: Catalent
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
